Patrick Cobb, MD
Hematology & Oncology · Billings, MTNPI 1710968219
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,369 of the $20,940 with a category attached, or 63.8%. Genentech USA, Inc. accounts for 68.3% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $15,155, more than ten times the $1,341 reported in 2019. Among hematology & oncology clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $307.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$14K
- Merck$3K
- Genentech, Inc.$814
- Eli Lilly$800
- Novartis$771
- G1 Therapeutics, Inc.$322
- plus $1K from 12 others
Across 1,807 payments — averaging $8142.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.9M
- Genentech, Inc.$1.2M
- Seagen Inc.$855K
- Novartis$811K
- AbbVie$483K
- Pfizer$417K
- plus $4M from 34 others
What the payments were for
- Consulting fees$13,36964%
- Travel & lodging$3,15615%
- Food & beverage$4,33321%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 15 | $14,294 |
| Merck | 14 | $2,578 |
| Genentech, Inc. | 10 | $814 |
| Eli Lilly | 1 | $800 |
| Novartis | 5 | $771 |
| G1 Therapeutics, Inc. | 2 | $322 |
| Tolmar, Inc. | 2 | $292 |
| Astrazeneca UK Limited | 2 | $270 |
| AstraZeneca | 2 | $165 |
| AVEO Pharmaceuticals, Inc. | 1 | $135 |
| Portola Pharmaceuticals, LLC | 1 | $126 |
| Johnson & Johnson | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 3 | $80 |
| Pfizer | 4 | $71 |
| United Therapeutics Corporation | 2 | $66 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Haemonetics Corporation | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,940 in reported general payments places this provider in the 95th percentile of 37 hematology & oncology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 62 | $745,690 |
| RevlimidLenalidomide | 33 | $614,194 |
| TasignaNilotinib Hcl | 22 | $369,777 |
| IbrancePalbociclib | 24 | $360,064 |
| XtandiEnzalutamide | 24 | $315,848 |
| KisqaliRibociclib Succinate | 20 | $288,628 |
| OnuregAzacitidine | 11 | $263,299 |
| WeliregBelzutifan | 12 | $250,227 |
| Lenalidomide | 14 | $171,131 |
| NubeqaDarolutamide | 17 | $153,119 |
| CalquenceAcalabrutinib Maleate | 11 | $129,983 |
| OxycontinOxycodone Hcl | 21 | $92,620 |
| Abiraterone Acetate | 27 | $51,401 |
| Imatinib Mesylate | 35 | $50,498 |
| OrgovyxRelugolix | 12 | $30,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Kisqali | $771 | $658,40542 claims |
| PfizerIbrance, Eliquis | $71 | $382,24159 claims |
| E.r. Squibb & Sons, L.L.C.Onureg | $80 | $263,29911 claims |
| MerckWelireg | $2,578 | $250,22712 claims |
| AstraZenecaCalquence | $165 | $129,98311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 37 hematology & oncology providers in Montana.
Other hematology & oncology in Billings
- Michael KiddBillings$507
- Martin LucasBillings$187
- David ChristiansonBillings$163
- Benjamin MarchelloBillings$82
- Troy FiddlerBillings$75
- Brock WhittenbergerBillings$0
- Thomas WeinerHelena$14K
- Aaron FrankeSidney$11K
- Carolyn AksHavre$9K
- Karl GuterGreat Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.